Open AccessOutcomes of combination therapy using aflibercept and dexamethasone intravitreal implant versus dexamethasone monotherapy for macular edema secondary to retinal vein occlusion
Author(s) -
Walid Harb,
Georgio Chidiac,
Georges Harb
Publication year - 2021
Publication title -
middle east african journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.357
H-Index - 25
eISSN - 0975-1599
pISSN - 0974-9233
DOI - 10.4103/meajo.meajo_297_19
Subject(s) - medicine , dexamethasone , aflibercept , macular edema , retinal vein , ophthalmology , occlusion , implant , combination therapy , retinal , bevacizumab , surgery , chemotherapy
The purpose of this study was to evaluate the efficacy of the combination therapy of intravitreal aflibercept 2 mg (Eylea ® ) and a sustained-release dexamethasone 0.7 mg intravitreal implant (Ozurdex ® ) versus dexamethasone alone in providing better visual acuity in eyes with macular edema (ME) secondary to retinal vein occlusion (RVO).